natgillin/translations-raw huggingface dataset:
subsequent reaction of the N-acetyl-L-aspartylated casein with ferric chloride; and 
(b) naknadne reakcije N-acetil-L-aspartiliranog kazeina s ferikloridom; i
an oligonucleotide sequence characterized in that it increases the transcription rate of a RNA typed as messenger RNA fragment encoding for a protein selected from the group consisting of enzymes, structural proteins, coenzymes, transporters, antibodies, hormones and regulators, as regulatory RNA fragment, as enzymatically active RNA fragment or as transfer RNA fragment, said oligonucleotide sequence having at least 80% sequence identity to SEQ ID NO: 1. 
Obigonukleotidna sekvenca naznačena fime da povećava razinu transkripcije DNA klasificirane kao glasnički DNA fragment koji kodira za protein iz grupe koja sadrži enzime, strukturalne proteine, koenzime, transporine proteine, antitijola, hormone i regulatore, kao regulirajući DNA fragment, kao enzimski aktivan DNA fragment ili kao prijenosni DNA fragment, ako je oligonukleotidna sekvenca najmanje 80% identična sekvenci SEQ ID No:1.
identifying a nucleic acid sequence that encodes the human immunoglobulin λ light chain variable domain of the antibody that binds the antigen of interest, and 
Metoda za dobivanje sekvence nukleinske kiseline koja šifrira varijabilnu domenu teškog i/ili lakog lanca koja se sastoji od:
The co-crystal of claim 9, wherein the molar ratio of VX-950 and 4-hydroxybenzoic acid is about 1:1 and the solvent is acetonitrile and the molar ratio of VX-950 and acetonitrile is about 1: 0.14 and wherein the co-crystal has one of the following: at least two of the four X-ray powder diffraction peaks at about 7.684, 8.599, 9.605, 9.938 °2-Theta, each with a standard deviation of about +/- 0.3 °2-Theta, or a DSC peak in its DSC thermogram at about 190.78 °C with a standard deviation of about +/- 5 °C. 
Sukristal u skladu s patentnim zahtjevom 6, naznačen time što molarni odnos između spoja sa strukturom [image] -hidroksibenzojeve kiseline iznosi otprilike 1:1, a molarni odnos između spoja sa strukturom [image] i acetonitrila iznosi otprilike 1:0,14 i ima najmanje dva od četiri signala difrakcije rendgenskih zraka na prahu na otprilike 7,684, 8,599, 9,605, 9,938 °2θ, od kojih svaki ima standardnu devijaciju od otprilike ± 0,3 °2θ, ili ima DSC signal u svom DSC termogramu na otprilike 190,78 °C, uz standardnu devijaciju od otprilike ± 5 °C.
an x-ray powder diffraction (XRPD) pattern substantially in accordance with the pattern shown in Figure 8. 
(111) uzorak difrakcije praha X-zraka (XRPD) uglavnom u skladu s uzorkom prikazanim na Slici 8.
The method of paragraph 1, wherein the biological sample is transcervical lavage fluid. 
Postupak prema zahtjevu 1, naznačen time, da biološki uzorak je intercervikalna plodna tekućina.
Process according to claim 14, wherein the processing agent, preferably aluminum sulfate or its hydrate, more preferably aluminum sulfate hexadecahydrate is dosed in one or more steps, preferably in one step to said aqueous calcium carbonate containing mineral slurry. 
Postupak prema zahtjevima 1 do 12, naznačen time da se sredstvo za obradu, poželjno aluminijev sulfat ili njegov hidrat, poželjnije aluminijev sulfat heksadekahidrat, dozira u jednom ili više koraka, poželjno u jednom koraku u navedenu suspenziju koja sadrži kalcijev karbonat koji sadrži mineral.
Pd(Ph3P)4] or through an aryl or heteroaryl lithium, in the presence of a tri-alkyltinhalide or hexaalkylditin [e.g., (CH3)3SnSn(CH3)3]. 
Prvi korak je prevođenje aril ili heteroaril bromida u odgovarajući trialkil intermedijer uporabom na primjer, Pd katalizirane reakcije [t.j.
a CDRL2 amino acid sequence selected from the group consisting of SEQ ID NOS:10, 20, 30, and 40; and a CDRL3 amino acid sequence selected from the group consisting of SEQ ID NOS:11, 21, 31, and 41. 
CDRL2 sekvencu aminokiselina SEQ ID NO: 40; 1 CDRL3 sekvencu aminokiselina SEQ ID NO: 41, i navedenu varijabilnu regiju teškog lanca koji sadrži: CDRHI sekvencu aminokiselina SEQ ID NO: 34;
Beverage according to claim 21, wherein the hydroxyhydrocarbyl residue comprises at least two hydroxyl groups. 
Upotreba prema zahtjevu 29 ili 30, naznačena time, što hidroksihidrokarbilni ostatak sadržava najmanje dvije hidroksilne skupine.
The method according to any one of claims 1 to 18, wherein said herbicide composition comprises at least one further active ingredient chosen from among: EPSPS-inhibitors, glyphosate; glutamine synthetase inhibitors, glufosinate; ACCase inhibitors, dims, fops, or dens; PPO-inhibitors, saflufenacil; fungicides, pyraclostrobin; or agronomically acceptable salts or esters thereof; and the Brassica plant expresses a trait of tolerance to said further active ingredients. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 18, naznačen time što navedena herbicidna smjesa sadrži najmanje jedan dodatni aktivni sastojak, kojeg se bira između: inhibitora EPSPS, glifosata; inhibitora glutamin-sintetaze, glufosinata; inhibitora ACCaze, dimova, fopova ili denova; inhibitora PPO, saflufenacila; fungicida, piraklostrobina; ili njihovih agronomski prihvatljivih soli ili estera; te gdje biljka iz roda Brassica pokazuje karakteristiku otpornosti na navedene dodatne aktivne sastojke.
12), said residues of the sequence optionally including side chain protection; and coupling the fifth fragment to the third fragment followed by removing the side chain protecting groups in order to provide an insulinotropic peptide of the formula HX8EX10TFTSDVSSYLEGQAAKEFIAWLVKX35R (SEQ. 
12), navedeni ostaci sekvence po izboru uključuju zaštitu bočnog lanca; te 1) kupiranje petog fragmenta na treći fragment i nakon toga uklanjanje zaštitnih skupina s bočnog lanca da bi so pribavio inzulinotropni peptid formule HX*EX'TFTSDVSSYLEGQAAKEFIAWLVKX* R (SEQ.
Aspect 5. The system of aspect 1 wherein the electric heater comprises an open channel structure. 
Sustav (10) prema zahtjevu 1, pri čemu električni grijač (14) ima otvorenu strukturu kanala.
the crystal modification C of racemic syn-3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-isopropyl-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-yl)-amide as defined in claim 1, or the composition as defined in claim 4; 
kristalne modifikacije C racemata (9-izopropil-1,2,3,4-tetrahidro-1,4-metano-naftalen-5-il)-amida sin-3-difluorometil-1-metil-1 H-pirazol-4-karboksilne kiseline kako je definirano u zahtjevu 1, ili pripravka kako je definirano u zahtjevu 4;
and the second binding domain comprises: a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 184; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 185; or (c) a VH domain as in (a) and a VL domain as in (b). 
Protutijelo anti-CD3 koje je bispecifično protutijelo, naznačeno time, da bispecifično protutijelo obuhvaća anti-CD3-ogranak koji obuhvaća prvu domenu vezanja, koja sadrži (a) VH domenu koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 184 i (b) VL domenu koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 185, te anti-HER2-ogranak koji obuhvaća drugu domenu vezanja, koja sadrži (a) VH domenu koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 270 i (b) VL domenu koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 271.
Various forms of inhalers (1) are known, one subset of these inhalers provide a dose of medicament from a canister in which the medicament is stored under pressure along with a suitable propellant. 
Poznati su različiti oblici inhalatora (1), a jedan podskup su inhalatori kojima se odmjerava doza medikamenta iz spremnika u kojem je medikament smješten pod tlakom pomoću odgovarajućeg potiskujućeg plina.
The anti-IL-5 antibody for the use as claimed in claim 5, wherein the mean plasma concentration of said antibody is 34.1 ± 12.1 µg/mL to 38.2 ± 9.1 µg/mLand/or wherein the AUC(0-inf) of said antibody is 1110 ± 372 µg×day/mL to 1196 ± 254 µg×day/mL. 
Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 5, naznačeno time što je srednja koncentracija u plazmi navedenog protutijela 34,1 + 12,1 ug/ml do 38,2 + 9,1 ug/ml i/ili što je AUC(o.<) Za navedeno protutijelo 1110 + 372 ugxdan/ml do 1196 + 254 ugxdan/ml.
A mat according to claim 1, wherein said elastic base part is made of polyurethane foam. 
Postupak proizvodnje otirača prema zahtjevu 1, naznačen time da je navedeni materijal elastične podloge poliuretanska pjena.
This general method can be illustrated in more detail as follows:- (Q = an amino-protecting group and, R, R1, R2, R3 and Y are as defined for formula [I]); 
Q (II) (Q = amino-zaštitna grupa i R, R', R', R*i Y su kao što je definirano za formulu /1/); ili
A compound according to formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein: 
Spoj u skladu sa formulom (I): [image] ili stereoizomer, tautomer, njegova farmaceutski prihvatljiva sol ili solvat, gdje: prsten A je C3-6 karbocikl;
In addition some medications have been studied to decrease the opioid “hunger” of addicts. 
Dodatno su bili proučavani neki lijekovi za smanjivanje "gladi" ovisnika za opioidima.
the amino acid sequence of one amino acid sequence selected from the group consisting of SEQ ID NOS: 142, 143 and 147-151. 
sekvencu aminokiseline od jedne sekvence aminokiseline izabrane iz grupe koja se sastoji od SEQ ID BR: 142, 143 I 147-151.
The method as in embodiment 13, wherein color pigments (13) are applied in a separate step in dry form and bonded by the water based drops. 
Metoda u skladu sa patentnim zahtjevom 12, gdje su pigmenti boje (13) naneseni u odvojenom koraku u suhom obliku i spojeni kapima koje su u osnovi voda.
The pharmaceutical composition according to claim 1 or 2, wherein the active agent has an average particle size of less than 300 µm, preferably less than 250 µm. 
Farmaceutski sastav prema zahtjevu 1 ili 2, naznačen time, da djelatno sredstvo ima prosječnu veličinu čestice koja je manja od 300 um, poželjno manja od 250um.
The boom mountable robotic arm of claim 9 wherein said selectively interruptible conductor comprises a stationary conductor between free distal ends of first and second posts of said at least one electrically insulated support post and a rotatable conductor extending from said free distal end of said second post and being selectively connectable to a distal end of a third post of said at least one electrically insulated support post. A boom mountable robotic arm for temporarily supporting an elongate conductor comprising: 
Robotska ruka koja se može montirati na krak dizalice prema zahtjevu 9, naznačena time, da navedeni vodič koji se može selektivno prekidati, sadrži nepomičan vodič između slobodnih distalnih krajeva od prvog i drugog podupirača od navedenih barem jednog električno izoliranog podupirača, te rotacijski vodič koji se proteže od navedenog slobodnog distalnog kraja od navedenog drugog podupirača i koji je selektivno moguće spojiti na distalni kraj od trećeg podupirača od navedenih barem jednog električno izoliranog podupirača.
The footing according to claim 8, characterized in that at least some of said covering panels (16, 17, 18a, 18b) are made of molded technopolymer. 
Postolje u skladu s patentnim zahtjevom 8, naznačeno time, da su barem neke od navedenih pokrovnih ploča (16, 17, 18a, 18b) načinjene od oblikovanog tehnopolimera.
Technical Solution To achieve the objects, the present invention provides a method of transmitting a signal, includes generating a second pilot signal including a layer-1 information region for assigning layer-1 information, arranging the generated second pilot signal in a preamble of a signal frame, and arranging a physical layer pipe (PLP) in a specific region ofthe layer-1 information region, and modulating the signal frame and transmitting the signal frame via at least one radio frequency (RF) channel. 
Postupak prijenosa emitiranja okvira signala digitalne televizije, DTV, naznačen time, što se sastoji od: generiranja ($531) sloja-1 informacije, sloj-L informacije je fizički parametar za signalizaciju voda na fizičkom sloju, PLP, isporukom servisnog toka; izgradnje (S533) okvira signala koji se sastoji od korisnih sadržaja i uvoda, uvod obuhvaća prvi pilot signal koji prethodi drugom pilot signalu, drugi pilot signal uključuje sloj-!1 informacije u čemu PLP je uključen u korisne sadržaje i drugi pilot signal, i prijenosa okvira signala putem najmanje jedne radio frekvencije, RF, kanala.
The present invention relates to a method of prophylaxis or treatment of systemic diseases in cats, wherein the method comprising administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to a cat in need of such a treatment. 
HR P20130696 T1 PATENTNI ZAHTJEVI Antagonist receptora 1 (AT-1) angiotenzina Il, naznačen time, da se upotrebljava u terapeutski djelotvornoj količini za liječenje kroničnih bolesti bubrega kod mačaka, pri čemu takav antagonist receptora 1 (AT-1) angiotenzina II je sartan.
Another example of combination therapy can be seen in treating diabetes and related disorders wherein the compounds of the present invention or salts thereof can be effectively used in combination with second active therapeutic, such as sulfonylureas, biguanides, meglitinides, thiazolidinediones, a-glucosidase inhibitors, other insulin secretogogues, insulin as well as the active agents discussed above for treating arteriosclerosis. 
Sljedeći primjer kombinacijske terapije može biti liječenje dijabetesa i povezanih poremećaja, gdje se spojeve prema ovom izumu ili njihove soli može se djelotvorno upotrijebiti u kombinaciji s drugim aktivnim terapijskim sredsvima, poput sulfonilurea, bigvanida, meglitinida, tiazolidindiona, inhibitora a-glukozidaze, drugih inzulinskih sekretagoga, inzulina, kao i aktivnim sredstvima prodiskutiranim gore, kod liječenja arterioskleroze.
Ki is calculated by the Cheng and Prustoff transformation: EPMATHMARKEREP where [L] is the concentration of a Radio-RUP25 Ligand used in the assay and KD is the dissociation constant of a Radio-RUP25 Ligand determined independently under the same binding conditions. 
Ki je kalkuliran, na primjer, pomoću Cheng and Prustoff transformacije: K; = IC: / (1 + [L1/Kp) gdje je [L] koncentraija Radiološki označenog RUP25 liganda korištenog u ispitivanju i K, je konstanta disocijacije Radiološki označenog RUP25 liganda određena neovisno od samih uvjeta ispitivanja.
Even more preferably, said colour intensity does not exceed 0.003 as calculated herein. 
Čak još poželjnije, spomenuti intenzitet boje ne prelazi 0,003, kako je ovdje izračunato.
is hydrogen or halo; and R6a is selected from the group consisting of halo, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. 
je vodik ili halo; a R6a je odabran iz skupine koju čine halo, supstituirani ili nesupstituirani aril, isupstituirani ili nesupstituirani heteroaril.
• addition of Sodium alginate and Coconut-palm mixture, 
dodavanje natrijevog alginata i smjese kokosa i palme, *
said heterocyclic group being unsubstituted or substituted by 1 to 3 substituents independently selected from the group consisting of substituents a1; and 
De gdje je navedena heterociklička skupina nesupstituirana ili je supstituirana s 1 do 3 supstituenta, koje se neovisno bira iz skupine koju čine supstituenti o; i
The organic layer was dried over Na2SO4. 
Organski sloj osuši se preko Na2SOxy.
The method according to claim 15 where the diseases are selected from the group consisting of asthma and chronic obstructive pulmonary disease (COPD). 
Uporaba u skladu s patentnim zahtjevom 13, naznačena time, da su bolesti karakterizirane opstruktivnim komponentama ili uzrokovane upalom poput astme i kronične opstruktivne plućne bolesti (KOPB).
computing means and means for a real time communication, with an operative Headquarter, said means embedding a function of immediate recognition of the risk factor of the event, according to detection of R.I.N. codes (Risk Identification Number) and O.N.U. codes (related to the identification of the product), and with access to a data base including the list of known dangerous goods, with reference to their chemical-physical features and the proper procedures of their treatment, with a further list of industrial plants able to provide treatment of that specific dangerous materials, with their location on the national territory. 
- > sredstvo za proračunavanje i sredstvo za komuniciranje (300) s operativnim stožerom u realnom vremenu, navedeno sredstvo uključuje funkciju trenutnog prepoznavanja faktora rizika događaja, u skladu s otkrivanjem R.I.N. kodova (Risk Identification Number) i O.N.U. kodova (povezanih s identifikacijom produkta), i pristupa bazi podataka koja uključuje popis poznate opasne robe u odnosu na njihove kemijsko-fizikalne značajke i odgovarajuće postupke za njihovu obradu, te daljnji popis industrijskih postrojenja sposobnih da izvrše obradu ovih posebnih opasnih tvari, s njihovom lokacijom na državnom teritoriju. HR P20130577 TI
Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. 
Štoviše, kada se to želi ili je potrebno, pogodna veziva, lubrikanti, dezintegrirajući agensi, kao i agensi boje mogu se dodati u smjesu.
The carabiner according to claim 1, wherein the constraint portion at the pocket comprises aligned through holes. The carabiner according to claim 1, wherein said bulb-shaped coupling portion comprises a shoulder, wherein the shoulder has a planar, convex surface with a continuous line profile, or convex surface with a broken line profile. 
Karabiner (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što navedeni dio za spajanje (13) ima izbočinu (14), gdje izbočina (14) ima ravnu, konveksnu površinu s profilom kontinuirane linije, ili konveksnu s profilom prekinute linije.
Phospholipids, in particular lecithins. 
6) Fosfolipide, posebno lecitine.
Composition of 100 mg of dry powder: 
Sastav 100 mg suhog praha:
A preferred process for the preparation of the compound of formula I comprises a step wherein the benzamidine moiety in the residue A is in the form of a precursor, preferably being the 1,2,4-oxadiazolin-5-one group, and is subsequently converted into the benzamidine by deprotection, in particular by hydrogenation (Bolton, R. E. et al, Tetrahedron Letters, Vol 36, No 25, 1995, pp 4471-4474). 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 131i farmaceutski prikladne pomoćne tvari. Postupak dobivanja spoja formule I u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u koraku u kojem je benzamidinski ostatak u ostatku A u obliku preteče, kao 1,2,4-oksadiazolin-5-onska skupina, i naknadno se prevodi u benzamidin skidanjem zaštite.
Viewed from a still further aspect the invention provides the use of a carbamate or organophosphate and a pyrethroid or pyrethrin for the preparation of topical sea lice treatment agent compositions for use in a method of treatment of farmed fish to combat infestation by multicellular ectoparasites with exoskeletons which method comprises topically exposing farmed fish, especially fish in cages, to a first and a second sea lice treatment agent sequentially, said first sea lice treatment agent being a carbamate or organophosphate and said second sea lice treatment agent being a pyrethroid or pyrethrin, wherein exposure to the first sea lice treatment agent is effected 10 minutes to 12 hours before exposure to the second sea lice treatment agent. 
Organofosfatni ili karbamatni pedikulicid, namijenjen upotrebi u postupku liječenja ljudskog subjekta radi borbe protiv infestacije višestaničnim ektoparazitima s egzoskeletom, gdje se navedeni postupak sastoji u topikalnoj primjeni na navedenom subjektu prvog i drugog pedikulicida, gdje je navedeni prvi pedikulicid karbamatni ili organofosfatni pedikulicid, a navedeni drugi pedikulicid je piretroidni ili piretrinski pedikulicid, naznačen time što se navedeni drugi pedikulicid primijenjuje između 15 minuta 1 12 sati nakon primjene navedenog prvog pedikulicida, te gdje se ta dva pedikulicida primijenjuje u obliku pripravka za topikalnu primjenu u obliku otopine, kreme, gela, regeneratora, disperzije, praška, losiona, spreja ili masti, gdje je najmanje jedan od pripravaka šampon ili regenerator.
A packaging according to any of the preceding claims, wherein the hinging part allows the sides to be rotated relative to each other within an angle of 200° or more, such as 240°, so as to open the packaging. 
Pakiranje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time, što zglobni dio omogućava da se strane zakreću jedna u odnosu na drugu unutar kuta od 200? ili više, odnosno kuta od 240", tada kada se pakiranje otvori.
A combination according to claim 4 wherein the corticosteroid is budesonide. 
Kombinacija sukladno patentnom zahtjevu 4, naznačena time, da je f2-agonist formoterol fumarat.
pressurising said organic material in a fluid to a pressure above 225 bar, and 
- > tlačenje navedenog organskog materijala u tekućem obliku tlakom iznad 225 bara,
The genetically modified mouse of claim 1, wherein the mouse expresses a humanized IL-6Ra wherein the endogenous mouse IL-6Ra gene has been replaced with a human sequence comprising a sequence that encodes an ectodomain of a human IL-6Ra. 
Genetički modificirani miš prema zahtjevu 1, naznačen time da miš eksprimira humanizirani 1I-6Ra. pri čemu je endogeni mišji IL-6Ra gen zamijenjen ljudskom sekvencom koja sadrži sekvencu koja kodira ektodomenu za ljudski IL-6Ra.
The process according to claim 1, wherein the liquid composition in step a) and in step b) is an aqueous solution. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 6 pri čemu je tekući sastav u koraku a) i u koraku b) vodena otopina.
The composition of Claim 8, which comprises a therapeutically effective amount of a B2 adrenergic receptor agonist and a steroidal anti-inflammatory agent. 
Sastav prema zahtjevu 8, koji sadrži terapeutski učinkovitu količinu agonista beta2-adrenergičkih receptora i steroidnog protuupalnog agensa.
or a pharmaceutically acceptable salt, ester, enol ether, enol ester, amide, acetal, ketal, orthoester, hemiacetal, hemiketal, hydrate, solvate or prodrug thereof. 
HR P20181268 T1 ili njihova farmaceutski prihvatljiva sol, ili njihov ester, enoleter, enolester, acetal, amid, ketal, ortoester, hemiacetal, hemiketal, hidrat, ili njihov solvat.
forming a plurality of tapered recesses in one of the main sides, wherein the tapered recesses form each a pointed angle and the sum of the pointed angles of all tapered recesses is 300 to 355 degrees and the protrusion of the recesses into the form is more than 20% but not more than 80% of the thickness of the planar form. 
formiranje mnoštva konusnih udubljenja (40) na jednoj od glavnih strana, pri čemu svako konusno udubljenje (40) tvori šiljasti kut i zbroj šiljastih kutova svih konusnih udubljenja (40) iznosi 300 do 355 stupnjeva i izbočenje udubljenja (40) u oblik je više od 20%, ali ne više od 80% debljine ravnog oblik.
A compound of formula (VIII): wherein R' is hydrogen and R is selected from benzyl, acetyl, benzoyl, trifluoromethanesulfonyl, benzenesulfonyl, p-toluenesulfonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl and benzyloxycarbonyl optionally substituted on the aromatic ring with up to three substituents selected from halogen, cyano and trifluoromethyl; or R' is trimethylsilyl and R is tert-butoxycarbonyl; or R and R' taken together with the nitrogen they are linked to form a phthalimido group. 
Spoj formule (XI) ili (XIa) [image] naznačen time da R’ jest vodik, a R je odabran od sljedećih: benzil, acetil, benzoil, trifluormetanesulfonil, benzenesulfonil, p-toluenesulfonil, metoksikarbonil, etoksikarbonil, tert-butoksikarbonil, aliloksikarbonil i benziloksikarbonil koji može biti supstituiran na aromatskom prstenu s do trima supstituentima odabrani od sljedećih: halogen, cijano i trifluorometil; ili R’ jest trimetilsilil, a R jest tert-butoksikarbonil; ili R i R’ uzeti zajedno s dušikovim atomom za koji su vezani tvore ftalimido-skupinu.